Tier 2 — strong

The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial

Fatemeh Javadi, Arman Ahmadzadeh, Shahryar Eghtesadi, Naheed Aryaeian, Mozhdeh Zabihiyeganeh, Abbas Rahimi Foroushani, Shima Jazayeri
Journal of the American College of Nutrition 2017 36(1):9

Bibliography

PubMed
PMID 27710596
DOI
10.1080/07315724.2016.1140093
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample50 women with rheumatoid arthritis
InterventionQuercetin 500 mg/day versus placebo
Duration8 weeks
EndpointsInflammatory measures; Symptoms and quality of life

What the study showed, in plain terms

Published in 2017, this source examined inflammation and clinical symptoms. Design: Randomized double-blind placebo-controlled trial. Sample/model: 50 women with rheumatoid arthritis. The exposure or intervention was Quercetin 500 mg/day versus placebo. Follow-up or treatment period: 8 weeks.

Pain, stiffness, disease-activity and disability scores and hs-TNF-alpha favored quercetin. Joint-count and ESR differences were not significant.

Small adjunctive study in women with established disease. It does not establish disease modification or replacement of arthritis treatment.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Inflammation: CRP, Pain and Human Trials. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Pain, stiffness, disease-activity and disability scores and hs-TNF-alpha favored quercetin.
  • Joint-count and ESR differences were not significant.
  • The recorded outcome domains were Inflammatory measures; Symptoms and quality of life.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus placebo; 8 weeks.

What this study can and cannot tell us

  • Small adjunctive study in women with established disease. It does not establish disease modification or replacement of arthritis treatment.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
The Adjunctive Effect of Quercetin on Postoperative Pain Management Following Cesarean Section: A Randomized Controlled Study
Eman Mohamed Elmokadem et al. · Drug design, development and therapy · 2025
Tier 2
The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial
Zohreh Sajadi Hezaveh et al. · Complementary therapies in medicine · 2019
Tier 2
Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study
Italo Corsale et al. · International journal of colorectal disease · 2018

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology